EP0041350A2 - Procédé et appareil pour l'élimination "on line" par filtration, de macromolécules d'un fluide physiologique - Google Patents

Procédé et appareil pour l'élimination "on line" par filtration, de macromolécules d'un fluide physiologique Download PDF

Info

Publication number
EP0041350A2
EP0041350A2 EP81302297A EP81302297A EP0041350A2 EP 0041350 A2 EP0041350 A2 EP 0041350A2 EP 81302297 A EP81302297 A EP 81302297A EP 81302297 A EP81302297 A EP 81302297A EP 0041350 A2 EP0041350 A2 EP 0041350A2
Authority
EP
European Patent Office
Prior art keywords
stream
plasma
macromolecules
patient
physiological solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP81302297A
Other languages
German (de)
English (en)
Other versions
EP0041350A3 (en
EP0041350B1 (fr
Inventor
Paul S. Malchesky
Yukihiko Nose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Foundation for Artificial Organs
Original Assignee
Japan Foundation for Artificial Organs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22551904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0041350(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Foundation for Artificial Organs filed Critical Japan Foundation for Artificial Organs
Publication of EP0041350A2 publication Critical patent/EP0041350A2/fr
Publication of EP0041350A3 publication Critical patent/EP0041350A3/en
Application granted granted Critical
Publication of EP0041350B1 publication Critical patent/EP0041350B1/fr
Expired legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3482—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter

Definitions

  • This invention relates to plasmapheresis and. more particularly to the removal of undesirable solutes from plasma in a plasmapheresis process.
  • Plasmapheresis (the removal of blood, separation of the plasma and the reinfusion of the blood cells) with or without the replacement of the patient's plasma by donor plasma, a plasma fraction, or other physiological solution, is becoming more useful in the clinical treatment of various disease states.
  • Such disease states have in common the presence of undesirable elevated levels of plasma solutes.
  • Such solutes due to their increased size) cannot be effectively removed by techniques such as dialyses and hemofiltration. Therefore plasma removal with the infusion of physiological solutions is effective in depleting their concentration.
  • Various disease states treated by plasmapheresis are as follows.
  • the treatments presently being carried out by plasmapheresis may be generally grouped into two types: (1) removal of an abnormal metabolite(s) or toxin(s) and (2) treatment of a disorder of the immune system.
  • Examples of the first type include hepatic support, hyper- triglyceridemia, hypercholesterolemia, and the removal of protein or lipid bound toxins.
  • Examples of the second type include myasthenia gravis, glomerulonephritis, macro- globulinemias, arthritis, and systemic lupus erythema- tosis.
  • antibodies specific for the acetycholine receptors are elevated. Removal of these antibodies by plasmapheresis shows improvement in the patients.
  • macroglobulinemia there is an increased level of gamma globulin. Reducing this level by plasmapheresis is clinically effective.
  • the conventional method of plasmapheresis employs a cell centrifuge involving bulky and expensive equipment which is not portable and is very costly, and carries with it potential hazards. Namely, essential plasma products are lost that are not being replenished in the substitution fluids and the potential exists for acquiring hepatitis. In addition, the effectiveness of the procedure is limited due to the limited removal that can be accomplished in discarding a limited volume. If conventional plasmapheresis were to be accepted for the treatment of many of these diseases there would be created a greater need for plasma products than could be met nationally. Obviously, to take advantage of plasmapheresis in treating these diseases, new techniques must be developed for removal of the plasma "toxins".
  • a further object of the invention is to provide a plasmapheresis method and apparatus of the above type wherein a physiological solution is withdrawn from a patient, treated by removing macromolecules of predetermined size, and returned to the patient in a continuous process.
  • a further object is to remove molecules from the plasma which form a macromolecule after adding a complexing agent to the plasma.
  • a further object of the invention is to provide a plasmapheresis apparatus for "on-line” removal of macromolecules of predetermined size from a patient's physiological solution that is simple in construction, inexpensive to manufacture, and highly effective in operation.
  • a method of removing macromolecules from a physiological solution including: securing a physiological solution stream such as blood from a patient; separating such physiological solution stream into a concentrated cellular element stream and a plasma stream containing macromolecules therein by either a centrifuge or a membrane filter; cooling such plasma stream to a temperature of between just above the freezing point of the plasma stream and 35° centigrade; filtering macromolecules of predetermined size out of the cooled plasma stream to form a filtered plasma stream; combining such filtered plasma stream and such cellular element stream to form a processed stream; heating the processed stream to body temperature; and returning the heated processed stream to the patient in a continuous operation.
  • the cooler cools the separated stream to a temperature between about just above the freezing point of the separated stream and about 35 * centigrade to cause such macromolecules to gel or precipitate.
  • a complexing agent may be added to the plasma to promote formation of macromolecules.
  • the invention also includes an apparatus for removing macromolecules from a patient's physiological solution such as blood including plasma separation means, such as a centrifuge or a membrane filter, for dividing a physiological solution containing macromolecules into a concentrated cellular element stream and a plasma stream, a cooler in fluid flow communication with the plasma separation means for receiving the plasma stream therefrom and cooling such plasma stream to cause the macromolecules therein to gel or precipitate, filter means such as a membrane filter in fluid flow communication with the cooling unit for receiving the cooled plasma stream therefrom and filtering such cooled plasma stream to remove macromolecules of a predetermined size therefrom, fluid flow communication means for receiving the filtered plasma stream from the filter means and for receiving the concentrated cellular element stream and combining the two last-named streams to form a processed stream for return to the patient.
  • plasma separation means such as a centrifuge or a membrane filter
  • a pump may be employed in fluid flow communication with the plasma separation means and with the patient to pump the physiological solution from the patient to the plasma separation means.
  • the physiological solution may be lympth or ascitic fluid.
  • the cooling unit cools the separated plasma stream to a temperature of between just above the freezing point of the separated plasma stream and approximately 35° centigrade.
  • a heater unit may be operatively secured to the fluid flow communication means at a point in such fluid flow communication means after which the filtered plasma stream and the concentrated cellular element stream are combined to heat the processed stream to approximately body temperature before it is returned to the patient.
  • the filter means may be encased in the cooling unit for receiving the cooled plasma stream therefrom to further cool such cooled plasma stream.
  • Cryoprecipitates Serum globulins that precipitate or gel on cooling at low temperatures (4-35°C) and redissolve on warming
  • Cryoqlobulins Homogenous proteins that have become physically altered (myeloma, mixtures of immunoglobulins (as IgG and (IgM, or immune complexes (as antigen and antibody), possible with complement (as in SLE) Mol. Wt. 100,000 - 1,800,000
  • Macromolecules Molecules of 100,000 daltons molecular weight or higher
  • Plasma exchange has been shown to be effective in the treatment of various diseases, including the immunologically based disease states. This technique, however, has severe limitations in chronic applications, such as limited removal related to the volume of exchange and dilution by the infusion solution and the requirement for plasma products. Removal-of the macromolecules as immune complexes by specific sorbents in most cases requires extensive development work. The nonspecific removal of macromolecules by membrane filtration makes the treatment simpler and more universal in application.
  • plasma is separated on-line from whole blood.
  • the plasma which contains the macromolecules -s then filtered through a membrane filter which rejects the macromolecules and passes the albumin and smaller size plasma solutes which are reinfused into the patient.
  • a membrane filter which rejects the macromolecules and passes the albumin and smaller size plasma solutes which are reinfused into the patient.
  • albumin with rheumatoid arthritis plasma and membranes of nominal pore size of 0.1 microns, over 97% passage of albumin was achieved with greater than 25% rejection in a single pass of rheumatoid factor and Clq binding immune complexes.
  • the increased levels of cryoprecipitates containing antigen and or antibody in the form of immune complexes with or without complement suggests that their removal could be therapeutic.
  • Modification of the on-line plasma filtration circuit is made to include a heat exchanger to cool the plasma to below 10°C before filtration.
  • a heat exchanger to cool the plasma to below 10°C before filtration.
  • FIGURE 1 illustrates the method and apparatus of the invention as applied to the filtration of blood, although it will be understood that any other type of physiological fluid such as, for example, lymph, ascitic fluid, etc., may be treated.
  • FIGURE 1 blood is drawn from a patient into line 10 and fed into a pump 12 from which it is pumped into a line 14 and then into membrane filter 1.
  • a centrifuge may be employed as the function at this point is to separate the blood into a plasma solution stream (fed into line 18) and a concentrated cellular element stream (which is fed into line 19).
  • the plasma solution is led down a line 18 to a cooling unit 20 where the plasma solution is cooled to a temperature of between just above the freezing point of the plasma solution and about 35° centigrade to cause the macromolecules to gel or precipitate.
  • the cooled plasma solution is led down the line 22 to membrane filter 2, where the macromolecules are retained (and the albumin and lower molecular weight components pass through).
  • the filtered plasma (plasma) minus larger molecular weight solute) is led through the line 24 to the juncture 26, where the filtered plasma stream and the concentrated cellular element stream are joined or united (to form a processed stream) and then fed into line 28 and thence into the heater unit 30.
  • the heater unit 30 heats the processed stream to body temperature. The heated processed stream is then fed into the line 32 and returned to the patient in a continuous process.
  • the cooling unit 20a is shown encasing the filter 2 (and a portion of the incoming line 22) such filter 2 being enclosed in a layer of insulation 34. This structure assures proper (cooled) temperature maintenance within filter 2 during the filtering process.
  • a complexing agent is an agent which will allow single or multiple plasma factors to form a complex of higher molecular weight.
  • agent could be a sorbing agent or ion exchange material such as, for example, heparin which forms complexes with cholesterol and lipid containing components.
  • FIGURES 1 and 2 outline filtration for the separation of plasma from whole blood.
  • a cell centrifuge could also be used in place of membrane filter 1 for the generation of the plasma flow stream.
  • the plasma which contains the factors of interest, is directed to a membrane filter 2 designed to filter out the macromolecule(s) of interest, but pass those plasma solutes of smaller size.
  • the plasma is then reunited with the blood flow (concentrated cellular element stream) from filter 1 (or in the case of a centrifuge the blood flow from the centrifuge) before being returned to the patient.
  • filter 1 For filter 1, a membrane with a normal porosity of 0.2-1 micron would be required to generate the plasma. Past investigations with membranes in the lower range porosity have indicated that sieving coefficients of certain plasma macromolecules in the normal and the disease states are low (less than 0.8). In addition, operational conditions of filter 1, including blood and plasma flows, and velocities and transmembrane pressures may seriously affect the sieving properties of the macromolecules of interest. The filtration of blood in filter 1 is cross flow. Filter 2, which employs a membrane with a porosity of nominally 0.01 to 0.2 microns, would be required to remove macromolecules of 100,000 daltons molecular weight or.greater.
  • the filtration of the plasma in this filter may be cross flow or conventional (flow directly into filtration media).
  • a recirculation circuit and an additional pump are required in cross flow.
  • a variable resistor (as a screw clamp) may be placed to regulate the rate of filtration.
  • Serum globulins that precipitate or gel on cooling,at low temperatures (nominally 35- 4°C and generally 25-4"C) and redissolve on warming may occur in a variety of disorders such as myeloma, kala-azar, macroglobinemia, malignant lymphoma, collagen diseases as lupus, glomerulonephritis, infectious mononucleosis, syphilis, cytomegalovirus disease, rheumatoid arthritis, and other autoimmune diseases.
  • the globulins may represent homogeneous proteins that have become physically altered (myeloma), mixtures of immunoglobulins (as IgG and IgM), or immune complexes (such as antigen and antibody), possibly with complement (as in systemic lupus erythematosus).
  • cryoglobulins refers to those abnormal globulins.
  • the molecular weight of cryoglobulins vary from 100,000 to 1,800,000 daltons molecular weight.
  • cryoglobulins will precipitate out at room temperature, but as a rule, sera have to be cooled to 10°C or lower, before precipitation occurs. With the cryoglobulins cooled to a level to cause precipitation or gelling the filtration of these substances from the plasma is greatly facilitated.
  • the advantage of .-his scheme over the direct filtration scheme without excessive cooling is that the membrane porosity or pore size may be increased allowing for higher sieving of the normal proteins in the plasma and therefore more efficient return to the patient.
  • cooling of the plasma would normally take place in the circuit the temperature decrease may not always be uniform or low enough therefore a heat exchange system woulc: be most desirable to cool the plasma.
  • the blood should be rewarmed by heater 30 to physiological temperature on its return to the patient.
  • the membranes were Tuffryn HT-100 (polysulfone) with pore size of 0.1 micron from Gelman Sciences (Ann Arbor, Michigan), XM300 (acrylic copolymer)(approximately 0.02 micron pore size) from Amicon (Lexington, Massachusetts), (VMWP-approximately 0.05 micron pore size) MF (mixed cellulose acetate and nitrate) from Millipore Corp. (Bedford, Massachusetts).
  • Plasma from a patient suffering from rheumatoid arthritis was procured by centrifugation. Such plasma contained elevated levels of rheumatoid factor and C l q binding immune complexes.
  • the membranes were assembled into small test cells giving a total surface area of 56 cm 2 .
  • the plasma was recirculated through the test cells at ambient temperature.
  • the plasma was filtered first through an Asahi filter. This filtration process reduces the concentration of macromolecules in the plasma.
  • the plasma was used after decantation following refrigeration. This procedure results in the removal of a significant amount of cryoglobulins from the plasma.
  • a 54-year old white female was selected with extremely aggressive seropositive rheumatoid arthritis who failed all accepted modes of therapy and in addition failed cytotoxic drugs including Methotrexate and Cytoxan.
  • the only therapeutic modality to which she has transiently responded has been plasmapheresis.
  • the subject's blood was treated by the method and apparatus of FIGURE 1, such treatment reducing her immune complex C 1q Binding ( ⁇ 74 u/ml.) from 2256 units down to 688 units with a resultant improvement in symptomatology.
  • FIGURES 3 and 4 In this experiment, a patient's plasma was treated by the method and apparatus of FIGURE 1. It will be noted in FIGURE 3 that the albumin loss was only about 20%, while as shown in FIGURE 4, the cryo-protein reduction was about 95%.
  • treatment time is normally about two to four hours, with roughly 1.7 to 3.0 liters of plasma being treated.
  • Controlled recirculation of the treated plasma from line 24 over to line 18 could be effected if desired.
  • the invention provides a method of removing macromolecules from a plasma solution including providing a plasma solution containing macromolecules including a minimum size thereof, cooling the plasma solution to a temperature not lower than just above the freezing point of the plasma solution, and filtering the plasma solution with a membrane filter 2 having a porosity up to said minimum size to remove macromolecules of predetermined size from the plasma solution.
  • Also provided is a method of removing macromolecules from a physiological solution such as blood including, securing a physiological solution from a patient, separating the physiological solution stream into a concentrated cellular element stream and a plasma stream containing macromolecules therein by either a membrane filter or a centrifuge, filtering macromolecules of predetermined size out of the plasma stream to form a filtered plasma stream, combining the filtered plasma stream and the cellular element stream to form a processed stream, and returning the processed stream to the patient in a continuous process.
  • the step of heating the processed stream to approximately body temperature before it is returned to the patient may also be included.
  • the membrane filter for removing the macromolecules out of the separated stream has a porosity of nominally 0.01 to 0.2 microns to pass macromolecules of approximately 70,000 molecular weight and below and reject or collect macromolecules of approximately 100,000 molecular weight and over.
  • the invention also contemplates an apparatus for removing macromolecules from a patient's physiological solution including, plasma separation means 1 for dividing;a physiological solution such as blood containing macromolecules into a concentrated cellular element stream and a plasma stream, a cooler 20 in fluid flow communication with the plasma separation means 1 for receiving the.plasma stream therefrom and cooling such plasma -.tream to cause the macromolecules therein to gel or precipitate, filter means 2 in fluid flow communication with the cooling unit 20 for receiving the cooled plasma stream therefrom and filtering such cooled plasma stream to remove macromolecules of a predetermined size therefrom, fluid flow communication means 26 for receiving the filtered plasma macrosolute stream from the filter means and for receiving the concentrated cellular element stream and combining said two last-named streams to form a processed 'stream for return to the patient in a continuous process.
  • plasma separation means 1 for dividing
  • a physiological solution such as blood containing macromolecules into a concentrated cellular element stream and a plasma stream
  • a cooler 20 in fluid flow communication with the plasma separation means
  • a pump 12 in fluid flow communication with the plasma separation means 1 and with the patient to pump the physiological solution from the patient to the plasma separation means 1.
  • the cooling unit 20 cools the separated plasma stream to a temperature of between just above the freezing point of the separated plasma stream and approximately 35° centigrade, although it is to be understood that the cooler 20 may be eliminated in certain instances.
  • the heater unit 30 is preferred, but may be eliminated if the temperature in the line 28 is near body temperature.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP81302297A 1980-05-29 1981-05-22 Procédé et appareil pour l'élimination "on line" par filtration, de macromolécules d'un fluide physiologique Expired EP0041350B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US154581 1980-05-29
US06/154,581 US4350156A (en) 1980-05-29 1980-05-29 Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid

Publications (3)

Publication Number Publication Date
EP0041350A2 true EP0041350A2 (fr) 1981-12-09
EP0041350A3 EP0041350A3 (en) 1982-02-17
EP0041350B1 EP0041350B1 (fr) 1986-03-12

Family

ID=22551904

Family Applications (1)

Application Number Title Priority Date Filing Date
EP81302297A Expired EP0041350B1 (fr) 1980-05-29 1981-05-22 Procédé et appareil pour l'élimination "on line" par filtration, de macromolécules d'un fluide physiologique

Country Status (6)

Country Link
US (1) US4350156A (fr)
EP (1) EP0041350B1 (fr)
JP (1) JPS5731869A (fr)
BR (1) BR8103271A (fr)
CA (1) CA1163517A (fr)
DE (1) DE3174039D1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3307830A1 (de) * 1983-03-05 1984-09-06 Hans Peter 5880 Lüdenscheid Berkenhoff Verfahren und vorrichtung zur exkorporalen reinigung von blut
EP0120445A3 (en) * 1983-03-24 1986-11-12 Intermedicat Gmbh Method and device for the selective extracorporeal separation of pathological and/or toxic blood components
EP0166325A3 (en) * 1984-06-16 1987-04-08 Intermedicat Gmbh Process and device for the selective separation of pathological and/or toxic species from blood or plasma with the use of filter candles
GB2184670A (en) * 1985-12-19 1987-07-01 Cleveland Clinic Foundation Thermofiltration of plasma
WO1989004840A1 (fr) * 1987-11-24 1989-06-01 Fasting Biotech A.S. Procede d'isolement du facteur viii de coagulation
US4872978A (en) * 1986-11-26 1989-10-10 Fabio Fasting Biotech A/S Device for the removal of cryoglobulins
EP0589572A1 (fr) * 1992-08-27 1994-03-30 Pall Corporation Traitement de liquides physiologiques contenant des proteines
WO2000038760A3 (fr) * 1998-12-29 2000-10-19 Occulogix Corp Methodes de traitement rheologique et systemes associes d'apherese

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4398906A (en) * 1979-12-11 1983-08-16 Frederic A. Bourke, Jr. Method for externally treating the blood
US4612007A (en) * 1981-06-16 1986-09-16 Edelson Richard Leslie Method and system for externally treating the blood
DE3147377A1 (de) * 1981-11-30 1983-06-01 Akzo Gmbh, 5600 Wuppertal Verfahren und vorrichtung zur extrakorporalen entfernung von an eiweisskoerpern gebundenen toxinen
US4582598A (en) * 1981-12-15 1986-04-15 Baxter Travenol Laboratories, Inc. Replacement fluid control system for a blood fractionation apparatus and the like
WO1983002059A1 (fr) * 1981-12-15 1983-06-23 Baxter Travenol Lab Appareil de fractionnement du sang
US4634417A (en) * 1982-12-06 1987-01-06 Georgetown University Process for treatment of tumors and apparatus therefor
US4684521A (en) * 1982-12-08 1987-08-04 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4613322A (en) * 1982-12-08 1986-09-23 Edelson Richard Leslie Method and system for externally treating the blood
US4683889A (en) * 1983-03-29 1987-08-04 Frederic A. Bourke, Jr. Method and system for externally treating the blood
FR2548541B1 (fr) * 1983-07-07 1986-09-12 Rhone Poulenc Sa Procede de plasmapherese et appareillage utilisable notamment pour ce procede
FR2548907B1 (fr) * 1983-07-13 1985-11-08 Rhone Poulenc Sa Procede de plasmapherese et appareillage utilisable notamment pour ce procede
DE3570188D1 (en) * 1984-02-24 1989-06-22 Kuraray Co Apparatus for the treatment of plasma
US4663049A (en) * 1984-07-05 1987-05-05 University Of Utah Process for therapeutic dissociation of immune complexes and removal of antigens
US4776964A (en) * 1984-08-24 1988-10-11 William F. McLaughlin Closed hemapheresis system and method
US4708713A (en) * 1984-11-16 1987-11-24 Anisa Medical, Inc. Method and system for removing immunosuppressive components from the blood of mammals
US4895558A (en) * 1985-07-15 1990-01-23 University Of Queensland Autologous plasma delipidation using a continuous flow system
JPH0720986B2 (ja) * 1985-10-07 1995-03-08 日本ケミカルリサ−チ株式会社 生理活性物質の製造法
US4728430A (en) * 1986-02-10 1988-03-01 Millipore Corporation Diafiltration method
US4789482A (en) * 1986-02-10 1988-12-06 Millipore Corporation Method for separating liquid compositions on the basis of molecular weight
US5053127A (en) * 1987-01-13 1991-10-01 William F. McLaughlin Continuous centrifugation system and method for directly deriving intermediate density material from a suspension
US4944883A (en) * 1987-01-13 1990-07-31 Schoendorfer Donald W Continuous centrifugation system and method for directly deriving intermediate density material from a suspension
US4883462A (en) * 1987-01-30 1989-11-28 Baxter Travenol Laboratories, Inc. Blood extraction assist apparatus and method
US5188588A (en) * 1987-11-25 1993-02-23 Baxter Internatonal Inc. Single needle continuous hemapheresis apparatus and methods
US4851126A (en) * 1987-11-25 1989-07-25 Baxter International Inc. Apparatus and methods for generating platelet concentrate
US5484396A (en) * 1988-11-17 1996-01-16 Naficy; Sadeque S. Method and device for treatment of HIV infections and AIDS
US5474772A (en) * 1989-08-02 1995-12-12 Cobe Laboratories, Inc. Method of treatment with medical agents
US5418130A (en) * 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US5256294A (en) * 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
SE9100142L (sv) 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
EP0531540B1 (fr) * 1991-03-26 1996-07-10 Otsuka Pharmaceutical Factory, Inc. Procede et dispositif de filtration du plasma
US5217618A (en) * 1991-08-26 1993-06-08 Terumo Kabushiki Kaisha Plasma purification treatment
US5690835A (en) * 1991-12-23 1997-11-25 Baxter International Inc. Systems and methods for on line collection of cellular blood components that assure donor comfort
US5549834A (en) * 1991-12-23 1996-08-27 Baxter International Inc. Systems and methods for reducing the number of leukocytes in cellular products like platelets harvested for therapeutic purposes
US5330420A (en) * 1992-01-13 1994-07-19 Therakos, Inc. Hemolysis detector
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5744038A (en) 1993-07-30 1998-04-28 Aruba International Pty Ltd. Solvent extraction methods for delipidating plasma
AU3815795A (en) * 1994-11-09 1996-06-06 Mitsubishi Rayon Company Limited Hollow-filament plasma-filtering membrane and plasma-filtering module
AUPN030794A0 (en) 1994-12-22 1995-01-27 Aruba International Pty Ltd Discontinuous plasma or serum delipidation
US5628727A (en) * 1995-08-15 1997-05-13 Hakky; Said I. Extracorporeal virioncidal apparatus
GB9600426D0 (en) * 1996-01-10 1996-03-13 Ed Geistlich Sohne A G Compositions
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
ATE471150T1 (de) * 1996-03-26 2010-07-15 Kopreski Michael S Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US6627151B1 (en) * 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US20060199811A1 (en) * 1997-07-31 2006-09-07 Pfirrmann Rolf W Method of treatment for preventing or reducing tumor growth in the liver of patient
US8304390B2 (en) * 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US20090233276A1 (en) * 1998-09-22 2009-09-17 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
US6821968B2 (en) 2001-09-26 2004-11-23 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Stable taurolidine electrolyte solutions
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US8535258B2 (en) * 2000-03-24 2013-09-17 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US7291122B2 (en) * 2000-03-24 2007-11-06 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US8597516B2 (en) * 2000-05-16 2013-12-03 Immunocept, L.L.C. Methods and systems for colloid exchange therapy
US6787040B2 (en) 2000-05-16 2004-09-07 Immunocept, L.L.C. Method and system for colloid exchange therapy
US7439052B2 (en) * 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US7407662B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7407663B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US20030127386A1 (en) * 2001-06-25 2003-07-10 Bomberger David C. Hollow fiber contactor systems for removal of lipids from fluids
WO2003000381A1 (fr) * 2001-06-25 2003-01-03 Lipid Sciences, Inc. Systemes de contacteur a fibres creuses destines a l'elimination de lipides provenant de liquides
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
EP1412045A4 (fr) * 2001-06-25 2007-05-02 Lipid Sciences Inc Systemes et procedes d'elimination de lipides contenus dans des fluides a l'aide d'un solvant permettant
US6991727B2 (en) * 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
DE60239470D1 (de) * 2001-07-25 2011-04-28 Oncomedx Inc Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
US20030036720A1 (en) * 2001-08-17 2003-02-20 Spencer Dudley W.C. Hemodialysis assembly and method
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
US6852231B2 (en) 2002-02-15 2005-02-08 Denco, Inc. Spin-hemodialysis assembly and method
CA2495459C (fr) * 2002-08-13 2009-10-27 Arbios Technologies Inc. Therapie d'echange de plasma selectif
KR100459432B1 (ko) * 2002-08-21 2004-12-03 엘지전자 주식회사 이동통신 시스템의 핸드오버 처리방법
EP1534243A4 (fr) * 2002-08-26 2008-08-13 Lipid Sciences Inc Traitement de la maladie d'alzheimer au moyen de particules de proteine degraissees
US20080160107A1 (en) * 2002-09-10 2008-07-03 Nitric Biotherapeutics, Inc. Use of nitric oxide gas to treat blood and blood products
US7207964B2 (en) * 2003-03-17 2007-04-24 Hemavation, Llc Apparatus and method for down-regulating immune system mediators in blood
US7169303B2 (en) * 2003-05-28 2007-01-30 Hemocleanse Technologies, Llc Sorbent reactor for extracorporeal blood treatment systems, peritoneal dialysis systems, and other body fluid treatment systems
DE10324668A1 (de) * 2003-05-30 2004-12-23 Fresenius Medical Care Deutschland Gmbh Vorrichtung zur extrakorporalen Bestrahlung einer Bilirubin enthaltenden Flüssigkeit und Verfahren hierfür
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
DK1641421T3 (en) * 2003-07-03 2019-03-11 Hdl Therapeutics Inc Methods and apparatus for producing HDL particle derivatives of reduced lipid content
US6960803B2 (en) * 2003-10-23 2005-11-01 Silicon Storage Technology, Inc. Landing pad for use as a contact to a conductive spacer
US20050197496A1 (en) * 2004-03-04 2005-09-08 Gtc Biotherapeutics, Inc. Methods of protein fractionation using high performance tangential flow filtration
CN2698358Y (zh) * 2004-04-06 2005-05-11 上海江夏血液技术有限公司 血液过滤装置
WO2005107802A2 (fr) * 2004-04-30 2005-11-17 Biopheresis Technologies, Llc Procede et systeme permettant d'eliminer les tnfr1, les tnfr2, et les il2 chez des patients
US20060130159A1 (en) * 2004-12-09 2006-06-15 Nick Masiello Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum
JP4899040B2 (ja) * 2005-07-01 2012-03-21 国立大学法人 岡山大学 ビリルビン変性器及びビリルビン透析装置
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
WO2007049286A1 (fr) * 2005-10-27 2007-05-03 Tata Memorial Centre Systeme de separation ex vivo de particules de chromatine apoptotiques du sang ou du plasma
US7531632B2 (en) * 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
AT505433B1 (de) * 2007-07-06 2009-10-15 Technoclone Ges M B H Plasmafiltration
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
US8672869B2 (en) * 2007-10-30 2014-03-18 Bellco S.R.L. Kit, system and method of treating myeloma patients
WO2009065082A1 (fr) * 2007-11-14 2009-05-22 Pathway Medical Technologies, Inc. Procédés et systèmes pour la collecte et l'analyse d'échantillons biologiques
US20110197628A1 (en) * 2008-01-25 2011-08-18 Baylor College Of Medicine Cryoaggregate filtration for the treatment of cardiomyopathy and other autoimmune diseases
US8202240B2 (en) * 2008-08-12 2012-06-19 Caridianbct, Inc. System and method for collecting plasma protein fractions from separated blood components
US8123713B2 (en) * 2008-08-12 2012-02-28 Caridian Bct, Inc. System and method for collecting plasma protein fractions from separated blood components
WO2011090943A1 (fr) * 2010-01-22 2011-07-28 Baylor College Of Medicine Retrait d'albumine pathologique du plasma d'un sujet
US9694128B1 (en) * 2010-02-24 2017-07-04 Brian LeBerthon Device and method for administering an anti-cancer substance
AU2013222414B2 (en) * 2012-02-21 2018-02-15 Cytonics Corporation Systems, compositions, and methods for transplantation
US10624924B2 (en) 2012-03-12 2020-04-21 Grifols, S.A. Method and device for treating blood cholesterol disorders
US20160022895A1 (en) * 2013-01-15 2016-01-28 Takatori Corporation Stock solution concentrating device, stock solution treatment device, and circulation-type treatment device
US9227005B2 (en) 2013-03-14 2016-01-05 Brian J LeBerthon Method and device for treating cancer
MX384222B (es) 2013-07-05 2025-03-14 Lab Francais Du Fractionnement Matriz de cromatografia de afinidad.
AU2015201496B2 (en) 2014-06-03 2019-10-31 Grifols Worldwide Operations Limited Use of plasmapheresis to treat blood pressure disorders
JP6527884B2 (ja) * 2014-12-26 2019-06-05 旭化成メディカル株式会社 体腔液処理システム
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US11027052B2 (en) 2017-11-22 2021-06-08 HDL Therapuetics, Inc. Systems and methods for priming fluid circuits of a plasma processing system
EP3731814A4 (fr) 2017-12-28 2021-09-29 HDL Therapeutics, Inc. Procédés de conservation et d'administration de pré-bêta lipoprotéines de haute densité extraites à partir de plasma humain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579441A (en) * 1968-04-19 1971-05-18 Hydronautics Blood purification by dual filtration
US3705100A (en) * 1970-08-25 1972-12-05 Amicon Corp Blood fractionating process and apparatus for carrying out same
US3788319A (en) * 1971-07-30 1974-01-29 Univ Iowa State Res Found Inc System for exchanging blood ultrafiltrate
US3802432A (en) * 1972-05-18 1974-04-09 I Djerassi Apparatus for filtration-leukopheresis for separation and concentration of human granulocytes
US4006078A (en) * 1974-07-08 1977-02-01 The United States Of America As Represented By The Secretary Of Agriculture Preparation of soluble edible protein from leafy green crops
US3941356A (en) * 1974-11-13 1976-03-02 The United States Of America As Represented By The Department Of Health, Education And Welfare Method and apparatus for continuous mixing of blood plasma and additives
GB1558370A (en) * 1975-09-26 1979-12-28 Asahi Chemical Ind Blood treating apparatus
DE2553416A1 (de) * 1975-11-27 1977-06-02 Hager & Elsaesser Verfahren zum abtrennen von geloesten stoffen aus einer loesung
US4103685A (en) * 1976-01-05 1978-08-01 Lupien Paul J Method and apparatus for extravascular treatment of blood
JPS52155888A (en) * 1976-06-22 1977-12-24 Mitsui Toatsu Chemicals Device for continuously removing material in blood flow
US4111199A (en) * 1977-03-31 1978-09-05 Isaac Djerassi Method of collecting transfusable granulocytes by gravity leukopheresis
JPS5416896A (en) * 1977-06-21 1979-02-07 Asahi Medical Co Blood dialyser
US4191182A (en) * 1977-09-23 1980-03-04 Hemotherapy Inc. Method and apparatus for continuous plasmaphersis
US4223672A (en) * 1979-02-08 1980-09-23 Baxter Travenol Laboratories, Inc. Variable volume plasma treatment chamber for an apparatus for the extracorporeal treatment of disease
US4215688A (en) * 1979-02-09 1980-08-05 Baxter Travenol Laboratories, Inc. Apparatus for the extracorporeal treatment of disease
US4350594A (en) * 1980-04-16 1982-09-21 Kuraray Co., Ltd. Blood purification using plural ultrafiltration stages

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3307830A1 (de) * 1983-03-05 1984-09-06 Hans Peter 5880 Lüdenscheid Berkenhoff Verfahren und vorrichtung zur exkorporalen reinigung von blut
EP0120445A3 (en) * 1983-03-24 1986-11-12 Intermedicat Gmbh Method and device for the selective extracorporeal separation of pathological and/or toxic blood components
EP0166325A3 (en) * 1984-06-16 1987-04-08 Intermedicat Gmbh Process and device for the selective separation of pathological and/or toxic species from blood or plasma with the use of filter candles
GB2184670A (en) * 1985-12-19 1987-07-01 Cleveland Clinic Foundation Thermofiltration of plasma
US4872978A (en) * 1986-11-26 1989-10-10 Fabio Fasting Biotech A/S Device for the removal of cryoglobulins
WO1989004840A1 (fr) * 1987-11-24 1989-06-01 Fasting Biotech A.S. Procede d'isolement du facteur viii de coagulation
EP0589572A1 (fr) * 1992-08-27 1994-03-30 Pall Corporation Traitement de liquides physiologiques contenant des proteines
WO2000038760A3 (fr) * 1998-12-29 2000-10-19 Occulogix Corp Methodes de traitement rheologique et systemes associes d'apherese
US6551266B1 (en) 1998-12-29 2003-04-22 Occulogix Corporation Rheological treatment methods and related apheresis systems

Also Published As

Publication number Publication date
US4350156A (en) 1982-09-21
CA1163517A (fr) 1984-03-13
BR8103271A (pt) 1982-02-16
EP0041350A3 (en) 1982-02-17
EP0041350B1 (fr) 1986-03-12
DE3174039D1 (en) 1986-04-17
JPH0134626B2 (fr) 1989-07-20
JPS5731869A (en) 1982-02-20

Similar Documents

Publication Publication Date Title
US4350156A (en) Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
Falkenhagen et al. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances
US8021318B2 (en) Methods of blood-based therapies having a microfluidic membraneless exchange device
JP5711330B2 (ja) 一部が蛋白質に結合した物質を取除く装置
CA1086235A (fr) Systeme d'elimination continue de substances contenues dans le sang par circulation extracorporelle
CA2247031A1 (fr) Techniques de separation membranaire/sorption selectives pour la recuperation du sang
US4966709A (en) Thermofiltration of plasma
CA1234523A (fr) Procede et appareil pour la separation du plasma
Chang‐sheng et al. An evaluation of a polyethersulfone hollow fiber plasma separator by animal experiment
US5080796A (en) Thermofiltration of plasma
Agishi et al. Double filtration plasmapheresis
Lysaght et al. Closed-loop plasmapheresis
JPS62258672A (ja) 透析濾過装置及び方法
JP2002526172A (ja) 生物学的流体フィルターおよびシステム
US5217618A (en) Plasma purification treatment
Siami et al. Current topics on cryofiltration technologies
CA1176574A (fr) Methode et appareil pour l'enlevement continu par filtration de macromolecules dans un liquide physiologique
CA1176573A (fr) Methode et appareil pour l'enlevement continu par filtration de macromolecules dans un liquide physiologique
Borberg Problems of plasma exchange therapy
DE102004037475A1 (de) Filtersystem zur membrangetrennten, adsorptiven Behandlung partikelhaltiger Flüssigkeiten
CA1170138A (fr) Methode et appareil pour debarrasser un liquide physiologique en circulation de ses macromolecules par filtration
Hout et al. Specific removal of anti-A and anti-B antibodies by using modified dialysis filters
Malchesky 8.3 EXTRACORPOREAL ARTIFICIAL ORGANS
Nosé et al. Therapeutic membrane plasmapheresis
Smith et al. Membrane plasmapheresis and the developing technology of plasma therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE DE FR GB IT SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Designated state(s): BE DE FR GB IT SE

17P Request for examination filed

Effective date: 19820524

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE DE FR GB IT SE

ET Fr: translation filed
REF Corresponds to:

Ref document number: 3174039

Country of ref document: DE

Date of ref document: 19860417

ITF It: translation for a ep patent filed
PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: B. BRAUN MELSUNGEN AKTIENGESELLSCHAFT

Effective date: 19861210

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19910513

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19910515

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19910521

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19910528

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19910530

Year of fee payment: 11

ITTA It: last paid annual fee
RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

27W Patent revoked

Effective date: 19910424

GBPR Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state
BERE Be: lapsed

Owner name: JAPAN FOUNDATION FOR ARTIFICIAL ORGANS

Effective date: 19920531

EUG Se: european patent has lapsed

Ref document number: 81302297.7

Effective date: 19910731

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: B. BRAUN MELSUNGEN AKTIENGESELLSCHAFT

Effective date: 19861210